-
In a phase II trial of capecitabine and gemcitabine for patients who had previously received an anthracycline for either as an adjuvant or for metastatic disease, overall response rate was 55% and the median time to progression was 11 months. These results were somewhat better for patients who were being treated for the first time for advanced disease (i.e., for recurrence after adjuvant therapy) when compared to those who were receiving the drugs as second line.
-
-
Dual-antiplatelet therapy with aspirin and clopidogrel is recommended for patients with known vascular disease or multiple risk factors for vascular disease. However, little is known about the long-term bleeding risk of such therapy.
-
-
Access-site bleeding is one of the major complications of percutaneous coronary intervention (PCI). It is associated with the need for blood transfusions, increased length of stay, and increased healthcare expenditure.
-
The can rapid-risk stratification of unstable angina Patients Suppress Adverse Outcomes with Early Implementation of the ACC/AHA Guidelines (CRUSADE) is a registry study of acute coronary-syndrome patients.
-
Many patients who receive pacemakers or implantable cardioverter defibrillators (ICDs) are chronically treated with antiplatelet agents, warfarin, or a combination of the two. In this paper, Tompkins and colleagues from the Johns Hopkins Hospital report the results of a retrospective review of antiplatelet and anticoagulant management in patients receiving cardiac-rhythm devices.
-
The evolution of percutaneous coronary intervention (PCI) techniques has resulted in PCI becoming a reasonable alternative to coronary artery bypass graft (CABG) surgery in selected patients with unprotected left-main coronary artery (ULMCA) stenosis.
-
The Medtronic Sprint-Fidelis ICD-lead family is associated with an increased risk for lead fracture.
-
Postural orthostatic tachycardia syndrome (POTS) is a disabling orthostatic intolerance that mainly occurs in pre-menopausal women.
